Pirtobrutinib plus Pola-R-CHP for newly diagnosed non-GCB DLBCL
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination of targeted therapy (pirtobrutinib) with standard chemotherapy (Pola-R-CHP) for people newly diagnosed with a type of large B-cell lymphoma that is not the germinal center B-cell subtype. The goal is to see if adding pirtobrutinib helps the treatment work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have a confirmed diagnosis of non-GCB DLBCL, a specific subtype of large B-cell lymphoma.
- You must have at least one measurable tumor seen on a PET/CT scan done within the last 28 days.
- You must not have received any previous treatment for lymphoma.
- You must be generally healthy, with adequate organ and bone marrow function, and an ECOG performance status of 0 to 2 (meaning you can care for yourself and are not bedridden).
- You must agree to use effective contraception during treatment and for 90 days after your last dose if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called pirtobrutinib combined with standard chemotherapy (R-CHOP) for people with a type of large B-cell lymphoma that hasn't been treated before. The goal is to see if adding this drug helps the treatment work better.
This trial tests a combination of three drugs—pirtobrutinib, lisaftoclax, and rituximab—for people with relapsed or refractory DLBCL who have already had at least one prior treatment. The goal is to see if this combination can help shrink or control the lymphoma.
This trial tests a combination of targeted therapy (Orelabrutinib) plus standard chemotherapy (Pola-R-CHP) for people with untreated non-GCB diffuse large B-cell lymphoma. The goal is to see if this new mix works better than the usual treatment.
This study tests a combination of five drugs (including a targeted therapy called polatuzumab vedotin) for patients with a specific type of aggressive lymphoma (DLBCL) that has never been treated before. The goal is to see if this combination works better and is safe for certain subtypes of this cancer.
This trial tests a combination of three targeted drugs (polatuzumab vedotin, zanubrutinib, and R-CHP) for people newly diagnosed with a specific subtype of DLBCL called non-GCB. The goal is to see if this powerful mix can work better than standard treatment.
This trial tests a new targeted therapy (pirtobrutinib) combined with standard chemo-immunotherapy, with or without an extra targeted drug (polatuzumab vedotin), for people whose large B-cell lymphoma has returned or not responded after prior BTK inhibitor treatment. The goal is to see if this combination can help control the cancer.
Hear when a new DLBCL - Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.